A Life-threatening Post-transfusion Reaction in an Individual With Sickle Cell Disease




Articles in Hematopoiesis are written for trainees by trainees, under the oversight of the ASH Trainee Council. The material published in Hematopoiesis is for informational purposes only. The opinions of the authors are their own and do not necessarily represent the official policy of the American Society of Hematology. ASH does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guarantee as to the same. Reliance on the information provided in this publication is solely at your risk.
A 57-year-old African American woman living with sickle cell disease (SCD; SS genotype) and baseline hemoglobin (Hgb) of 6.0 to 7.0 g/dL, presented to the emergency department (ED) with shortness of breath and pain consistent with a vaso-occlusive crisis. Her Hgb level was 6.3 g/dL; she was treated with supportive measures and received one unit of phenotypically matched packed red blood cell (PRBC) transfusion for symptomatic anemia. She showed improvements and was subsequently discharged.
She returned to the hospital eight days later with progressive fatigue, decreased oral intake, and dark urine. Initial evaluation revealed tachycardia (heart rate, 110/min), and physical examination was notable for scleral icterus. The rest of the physical exam was unremarkable.
Initial laboratory findings showed the following:
Test | Result | Range |
Hgb | 2.8 g/dL | 12-15 g/dL |
Hematocrit | 8.3% | 36-46% |
RBC count | 0.87 M/µL | 4.15-5.55 M/µL |
Mean corpuscular volume | 95.5 fL | 80-100 fL |
White blood cell count | 28.4 K/µL | 3.8-10.6 K/µL |
Platelet count | 125 K/µL | 150-450 K/µL |
Haptoglobin | < 30 mg/dL | 30-200 mg/dL |
Lactate dehydrogenase | 3,420 IU/L | < 250 IU/L |
Ferritin | 1,211 ng/mL | 11-307 ng/mL |
Total bilirubin | 2.7 mg/dL | < 1.2 mg/dL |
Direct bilirubin | 0.6 mg/dL | 0-0.3 mg/dL |
Reticulocyte count | 3.5% | 0.5-1.5% |
Fibrinogen | 263 mg/dL | 200-450 mg/dL |
D-dimer | > 20 µg/mL | < 0.50 µg/mL |
Prothrombin time | 19.8 seconds | 11.5-14.5 seconds |
Activated partial thromboplastin time | 32 seconds | 22-36 seconds |
Antibody screen | Negative | |
Direct antiglobulin test | Negative | |
High sensitivity Troponin | 650 ng/L | < 19 ng/L |
- Gardner K, Hoppe C, Mijovic A, et al. How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease. Br J Haematol. 2015;170:745-756.
- Chadebech P, Habibi A, Nzouakou N, et al. Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death. Transfusion. 2009;49:1785-1792.
- Coleman S, Westhoff CM, Friedman DF, et al. Alloimmunization in patients with sickle cell disease and underrecognition of accompanying delayed hemolytic transfusion reactions. Transfusion. 2019;59:2282-2291.
Drs. Sweidan, Vuyyala, Otrock, and Dabak indicated no relevant conflicts of interest.